Observational study · people
SS-31: 79.7 m better walk test vs untreated in Barth syndrome
Checked against the paper Observational studyPublished by PepVault
The takeaway
In a small, non-randomized comparison, people with Barth syndrome on elamipretide walked farther and were stronger over about 64 to 76 weeks than matched untreated patients.
- Kind
- Observational study
- Studied in
- People
- Published
- 2022
- Journal
- Orphanet J Rare Dis
What they tested
The team wanted to know whether people with Barth syndrome who took elamipretide did better over time than similar people who were never treated.
How the study was done
A retrospective, non-interventional comparison of 8 patients from the open-label extension of the TAZPOWER trial, who took 40 mg of elamipretide daily, with 19 untreated patients from a natural history group (people followed without treatment). The groups were compared using a propensity score model, a statistical way to match patients with similar traits.

What they found
On the 6-minute walk test, the main measure, the treated group did better by 79.7 m at week 64 (P = 0.0004) and by 91.0 m at week 76 (P = 0.0005). Muscle strength measured by handheld dynamometry was higher with elamipretide by 40.8 Newtons at 64 weeks and 56.7 Newtons at 76 weeks. The treated group also improved on a 5 times sit-to-stand test and on a multi-domain responder index, a combined score across several measures. Left ventricular stroke volume, the amount of blood the heart pumps per beat, rose from baseline with elamipretide but fell in the untreated group.
What it doesn’t show
This was a small study that looked back at existing records, with only 8 treated patients. The treated patients were not randomly assigned and knew they were on the drug, so the comparison with an untreated group gathered separately is weaker evidence than a placebo-controlled trial.
The paper
Hornby et al. Natural history comparison study to assess the efficacy of elamipretide in patients with Barth syndrome. Orphanet J Rare Dis. 2022.
The compound
More studies on SS-31
- SS-31 (elamipretide) eye drops missed main vision goal in LHON trialRandomized trial · people · 2024
- SS-31: wearable data grouped responders with 100% accuracyRandomized trial · people · 2023
- SS-31: no 12-week benefit, walk gains by 36 weeks open-labelRandomized trial · people · 2021
- SS-31 raised muscle ATP capacity after one dose in older adultsRandomized trial · people · 2021
- SS-31: walk distance rose with dose in 5-day MMPOWER trialRandomized trial · people · 2018
- SS-31: less kidney hypoxia after renal artery stenting in pilotRandomized trial · people · 2017
- Every study on SS-31
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.